Creative Medical Technology Holdings Inc

Noticias y eventos de Creative Medical Technology Holdings Inc (CELZ)

$1.140

0.000 (0.00%)Al cierre

Noticias de CELZ

Eventos de CELZ

8/20 10:00

Creative Medical Completes Patient Enrollment for CELZ-201 Clinical Trial

Creative Medical announced that all patients have now been enrolled and treated across the company's entire FDA-cleared ADAPT clinical trial evaluating CELZ-201 / Olastrocel, including the original study cohorts and the FDA-cleared opioid expansion cohort.

7/24 16:30

Creative Medical Files to Sell 5.58M Shares of Common Stock

Creative Medical files to sell 5.58M shares of common stock for holders

6/30 14:30

Creative Medical Technology Enters Agreement for Immediate Exercise of 2,790,340 Warrants

Creative Medical Technology announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 2,790,340 shares of common stock of the Company originally issued in October 2025, at a reduced exercise price of $1.60 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $4.5M, before deducting financial advisory fees. Roth Capital Partners is acting as the company's financial advisor for this transaction. In consideration for the immediate exercise of the existing warrants for cash, the company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 5,580,680 shares of common stock, at an exercise price of $1.60 per share upon the receipt of shareholder approval for a term of five years from the initial exercise date. The transaction is expected to close on June 30, 2026. The company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis